45th week of 2014 patent applcation highlights part 41 |
Patent application number | Title | Published |
20140329731 | GREASE COMPOSITION - The invention relates to a fatty composition including at least one basic polyol ester oil, at least one fatty-acid metal soap, at least one fluorinated polymer, and at least one sulfurous fatty acid ester, wherein the amount of active sulfur provided by the sulfurous fatty acid ester relative to the total fatty composition at 150° C. according to the ASTM D1662 standard is greater than or equal to 0.15 wt %. | 2014-11-06 |
20140329732 | COMBINATIONS OF 1-AZA-3,7-DIOXABICYCLO[3.3.0]OCTANE COMPOUNDS AND SILICIC ACID ESTERS AND THE USE OF SAME AS PRO-FRAGRANCES - The invention relates to combinations of 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds with silicic acid esters, methods for producing same, the use of same as pro-fragrances, as well as washing and cleaning agents, fabric softeners and cosmetics that contain same. The invention also relates to a method for prolonging the perception of fragrance in such agents. | 2014-11-06 |
20140329733 | PERFUME SYSTEMS - The present application relates to perfume delivery systems and consumer products comprising perfume delivery systems and or perfume raw materials, as well as processes for making and using such perfume delivery systems and consumer products. | 2014-11-06 |
20140329734 | ENZYME-CONTAINING WASHING OR CLEANING COMPOSITION COMPRISING CALCIUM NITRATE - The stabilization of enzymes in washing or cleaning compositions, especially in liquid aqueous washing or cleaning compositions, is possible through the use of only small amounts of calcium nitrate. | 2014-11-06 |
20140329735 | FRAGRANCING COMPOSITION OF PICKERING EMULSION TYPE - The present invention relates to a composition in the form of an oil-in-water emulsion, comprising, in a cosmetically acceptable medium: (i) a dispersed oily phase comprising at least one apolar hydrocarbon-based oil; (ii) a continuous aqueous-alcoholic phase comprising at least one C | 2014-11-06 |
20140329736 | Personal Care Compositions with Improved Hyposensitivity - The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil. | 2014-11-06 |
20140329737 | Development of Novel Macromolecule Transduction Domain with Improved Cell Permeability and Method for Using Same - The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions. | 2014-11-06 |
20140329738 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer. | 2014-11-06 |
20140329739 | ANTIBIOTIC PEPTIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREFOR - Disclosed are an antibiotic peptide and the like, having an amino acid sequence of Ac-Phe-Lys-Lys-Leu-Lys-Lys-Leu-Phe-Ser-Lys-Leu-Trp-Asn-Trp-Lys-NH | 2014-11-06 |
20140329740 | ANTI-INFECTIVE HYDROXY-PHENYL-BENZOATES AND METHODS OF USE - The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus | 2014-11-06 |
20140329741 | USE OF CYCLIC PEPTIDES FROM FLAXSEED FOR IMPROVING ANIMAL AND HUMAN HEALTH - The present application includes a method for improving human and animal health comprising administering an effective amount of a linus cyclopeptide (LCP) extract from flaxseed to a subject in need thereof. Also included are feeds, foodstuffs, functional food compositions, natural product compositions nutraceuticals and food additive compositions comprising an LCP extract from flaxseed. | 2014-11-06 |
20140329742 | THERAPEUTIC PEPTIDES - The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders. | 2014-11-06 |
20140329743 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers - A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to a-melanocortin stimulating hormone (a-MSH). | 2014-11-06 |
20140329744 | STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN - The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid. | 2014-11-06 |
20140329745 | HUMAN INSULIN ANALOGUE AND ACYLATED DERIVATIVE THEREOF - The present invention provides a human insulin analogue, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analogue and an application of the insulin analogue as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent. | 2014-11-06 |
20140329746 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 2014-11-06 |
20140329747 | Compositions and Methods for Treating Renal Failure - The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis. | 2014-11-06 |
20140329748 | Composition for Controlled Ovarian Stimulation - Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility. | 2014-11-06 |
20140329749 | ROBUST CONTROLLED-RELEASE PEPTIDE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a. 25-55 wt. % of at least one diacyl glycerol and/or at least one tocopherol; b. 25-55 wt. % of at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. 5-25 wt. % of at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein 0.1-10 wt. % of at least one peptide active agent comprising at least one somatostatin receptor agonist is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 2014-11-06 |
20140329750 | Growth Hormones with Prolonged In-Vivo Efficacy - The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. | 2014-11-06 |
20140329751 | METHOD FOR SENSITIZING CELLS TO CANCER THERAPY - Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth hormone and placental lactogen, or one or more of human prolactin, growth hormone and placental lactogen in conjunction with a cytotoxic agent. In some embodiments, the cytotoxic agent comprises a chemotherapeutic agent. | 2014-11-06 |
20140329752 | PEPTIDE ANTAGONISTS OF THE CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE - The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide. The embodiments further provide treatment methods, including methods of treating a migraine, the methods generally involving administering to an individual in need thereof an effective amount of a subject peptide or composition. | 2014-11-06 |
20140329753 | Angiogenic active lytic peptides - This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity. | 2014-11-06 |
20140329754 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide. | 2014-11-06 |
20140329755 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE - The present invention relates to method of treating arrhythmias or heart failure comprising co-administration of a late I | 2014-11-06 |
20140329756 | TEMPERATURE-RELEASE CATALYST FOR CROSS-LINKING HALYURONIC ACID DURING INJECTION - Systems and methods for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a temperature activated catalyst; injecting the mixture into a patient as a homogeneous fluid; activating the catalyst to cross-link the polymer at a predetermined temperature in a patient; and augmenting soft tissue with the biocompatible cross-linked polymer. | 2014-11-06 |
20140329757 | TUBULIN-INTERACTING PROTEIN, CALTUBIN, PROMOTES AXONAL GROWTH - A novel isolated protein, referred to herein as “caltubin”, is provided. Caltubin promotes axonal regeneration, and prevents or at least reduces axonal retraction in neurons. | 2014-11-06 |
20140329758 | PEPTIDE INHIBITORS FOR MEDIATING STRESS RESPONSES - The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides. | 2014-11-06 |
20140329759 | POLYETHYLENE GLYCOL-MODIFIED INTEGRIN BLOCKER HM-3 AND USE THEREOF - The present invention involves the pharmaceutical field, including integrin antagonists, which have the capacities of inhibiting angiogenesis of tumors, binding integrin. These antagonists are a kind of polypeptide, which was modified by polyethylene glycol and after modification, it can be used to treat tumors. The sequence and structure of these antagonists is mPEG-SC | 2014-11-06 |
20140329760 | PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer. | 2014-11-06 |
20140329761 | PREVENTION AND TREATMENT OF ACUTE INFLAMMATORY CONDITIONS - The present invention relates generally to methods for the prevention and treatment of acute inflammatory conditions in individuals using an agonist of the complement C3a receptor. | 2014-11-06 |
20140329762 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY - Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described. | 2014-11-06 |
20140329763 | ANTI-INFLUENZA NUCLEIC ACID, PEPTIDE NUCLEIC ACID AND PREPARATIONS THEREOF - Disclosed are an anti-influenza nucleic acid, peptide nucleic acid and preparations thereof. The nucleic acid of the invention consists of any one or several of SEQ ID NOs: 1-12, and any one or several of SEQ ID NOs: 13-24. The peptide nucleic acid of the invention consists of any one or several of SEQ ID NOs: 25-36, and any one or several of SEQ ID NOs: 37-48. The peptide nucleic acid preparation of the invention has effective ingredients of said peptide nucleic acids. The anti-influenza peptide nucleic acid of the invention is of high bioavailability and stable physical and chemical properties with no toxic or side effect and no drug tolerance. With low cost, the drugs can inhibit influenza virus replication and have good anti-virus effect. | 2014-11-06 |
20140329764 | NOVEL METHODS OF USE OF HSP70 FOR INCREASED PERFORMANCE OR TREATMENT OF HSP70 RELATED DISORDERS - The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70. | 2014-11-06 |
20140329765 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 2014-11-06 |
20140329766 | Prophylactic Compositions for Management of Microbial Infections in Patients with Brain Injury - The present disclosure pertains to antimicrobial compositions for intravenous administration to patients who have experienced a serious brain trauma, to reduce the risk of occurrence of post-trauma microbial infections. The antimicrobial compositions comprise an α-galacytosylceramide compound and one or more excipients. The present disclosure also pertains to the use of α-galacytosylceramide compounds for the manufacture of antimicrobial medicaments for intravenous administration to patients with serious brain traumas. The present disclosure also pertains to methods for the prophylactic use of the antimicrobial compositions to reduce the risks of occurrence of post-trauma microbial infections. | 2014-11-06 |
20140329767 | Compositions and Methods for Preventing and Treating Diseases and Environmentally Induced Health Disorders - Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, such as Onaway, Russet Burbank, Purple Valley or Bora Valley cultivars. These cultivars and combinations thereof provide a useful antioxidant source enriched in ferulic acid, caffeic acid, chlorogenic acids, ascorbic acid, anthocyanins, and rutin, isomers or derivatives thereof having antioxidant and/or anti-inflammatory activity. | 2014-11-06 |
20140329768 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES - Provided herein are compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acyclonucleotides, and ANP phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell. | 2014-11-06 |
20140329769 | Oxidized Regenerated Cellulose Hemostatic Powders and Methods of Making - The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient. | 2014-11-06 |
20140329770 | Compositions Comprising Phytoestrogens Receptor Beta Agonists and Dietary Fibers for Chemopreventive Treatment of Sporadic Adenomatous Polyposis - It is herein discloses compositions comprising a blend of dietary phytoestrogens receptor β agonists and dietary fibers for prevention and treatment of sporadic adenomatous polyposis. The aforementioned compositions proved to be effect in a clinical trial enrolling patients prone to polyp recurrence and at intermediate risk for colorectal cancer (CRC) development. | 2014-11-06 |
20140329771 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN - The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y—O—W (I), wherein Y and W are as defined in claim | 2014-11-06 |
20140329772 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY - The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene. | 2014-11-06 |
20140329773 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2014-11-06 |
20140329774 | INJECTABLE COMPOSITION CONTAINING PHOSPHATIDYLCHOLINE DEVOID OF SODIUM DEOXYCHOLATE AND PREPARING METHOD THEREOF - The present invention includes an injectable composition containing phosphatidylcholine including phosphatidylcholine; ethanol; propylene glycol and/or benzyl alcohol; polysorbate and/or macrogol 15 hydroxystearate; and a balance of water or water for injection, and a preparing method thereof. An injectable composition of the present invention includes no sodium deoxycholate, which is carcinogenic, and therefore a safer injectable composition of phosphatidylcholine can be prepared. | 2014-11-06 |
20140329775 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE - Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions. | 2014-11-06 |
20140329776 | Mitochondria-Targeted Antioxidants for Treatment of Age-Related Brain Disorders - A method for providing to a mammal a neuroprotective effect against a brain pathology that is associated with reactive oxygen species originating from mitochondria (mROS). The method includes the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effective to provide said neuroprotective effect. The SkQ mitochondria-targeted antioxidant may be administered either prophylactically or for treatment with respect to brain pathologies other than brain trauma or stroke, and may be administered for treatment of brain trauma or stroke. | 2014-11-06 |
20140329777 | METHODS TO TREAT INFECTIONS - Methods to treat infectious diseases are disclosed herein. Some embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) to treat infectious diseases. Other embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) and administration of one or more antibiotics to treat infectious diseases. | 2014-11-06 |
20140329778 | COMPOUNDS FOR USE AS ANTI-ULCER AGENT AND/OR ANTI-HELICOBACTER PYLORI AGENT AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to a compound according to formula I | 2014-11-06 |
20140329779 | Clear solid sticks with solubilized pharmaceutical agents - The invention discloses a solid transparent vehicle utilizing DBS in which a topical pharmaceutical active or cosmetic active is solubilized without the use of a monohydric and/or polyhydric alcohol thus providing a non-tacky, clear solid, which prevents segregation and insures uniformity in dosing. | 2014-11-06 |
20140329780 | INHIBITOR OF COLONISATION OF MUCOSA - The present invention relates in the first aspect to the use of aurintricarboxylic acids, derivatives, oligo- or polymers or salts, for inhibiting adherence and colonisation of microorganisms, like bacteria, on surfaces, in particular for use in mammals. That is, it has been recognized that aurintricarboxylic acids and derivatives thereof are suitable for inhibiting adherence and colonisation of mucosa, in particular, nasal mucosa. In another aspect, the present invention relates to a method for preventing adherence of microorganisms, like bacteria, to a surface comprising the step of treating the surface with aurintricarboxylic acids, derivatives, or salts thereof. Finally, the present invention relates the use of aurintricarboxylic acids, derivatives or salts for preventing adherence of bacterial pathogens, in particular, of the genus | 2014-11-06 |
20140329781 | METHODS FOR TREATING CARDIOVASCULAR DISORDER - The present invention relates to a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more antiplatelet agent along with one or more rate controlling excipients. | 2014-11-06 |
20140329782 | COMBINED THERAPEUTIC AGENT - The invention relates to a combined therapeutic agent, preferably for use at the prophylactic and/or therapeutic treatment of (A) in particular inflammatory diseases of the respiratory tract, in particular bronchopulmonary diseases, or of (B) in particular inflammatory diseases of the gastrointestinal tract, in particular of the intestine. The combined therapeutic agent comprises at least one vitamin D receptor agonist (VDA) and at least one further active substance, provided that the combined therapeutic agent does not contain any constituent and/or active substance from the group consisting of terpenes, monoterpenes, vasoconstrictors, alpha sympathomimetics and/or the physiologically harmless salts or derivatives thereof. | 2014-11-06 |
20140329783 | TRANSDERMAL HORMONE REPLACEMENT THERAPIES - Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems. | 2014-11-06 |
20140329784 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS - The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: | 2014-11-06 |
20140329785 | Conveniently Injectable or Implantable Sustained-Release Antioxidant Formulations for Therapies of Ocular Maladies or Cancer - The present embodiments provide for sustained release formulations of antioxidants that are useful in treating afflictions of the eye and tumors. | 2014-11-06 |
20140329786 | COMBINATION TREATMENT OF CANCER - The present invention relates to a combination comprising AZD5363, or a pharmaceutically acceptable salt thereof, and at least one androgen receptor signalling modulator selected from MDV-3100 (also known as enzalutamide), AZD3514, abiraterone (or an ester prodrug thereof: e.g. abiraterone acetate), and bicalutamide; or a pharmaceutically acceptable salt thereof. Each of these combinations may be useful in the treatment of cancer. The invention also relates to pharmaceutical compositions comprising such combinations, and further relates to methods of treatment comprising the simultaneous, sequential or separate administration of AZD5363, or a pharmaceutically acceptable salt thereof, with at least one androgen receptor signalling modulator as described above, to warm-blooded animal, such as a human for the treatment of cancer. The invention also relates to a kit comprising such combinations. | 2014-11-06 |
20140329787 | PHYTOPHTHORA PHOSPHOLIPASE C - The present invention relates to a novel | 2014-11-06 |
20140329788 | TESTOSTERONE GEL AND METHOD OF USE - The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use. | 2014-11-06 |
20140329789 | Methods for Inhibiting the Development of Huntington's Disease - This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof. | 2014-11-06 |
20140329790 | USE OF 5 alpha-ANDROSTANE-3 beta,5,6 beta-TRIOL IN PREPARATION OF NEUROPROTECTIVE DRUGS - Disclosed is the use of 5α-androstane-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof. | 2014-11-06 |
20140329791 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 2014-11-06 |
20140329792 | SYNTHETIC CATALASE/SUPEROXIDE DISMUTASE MIMETICS AND METHODS FOR TREATING VIRAL INFECTIONS - The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds. | 2014-11-06 |
20140329793 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug. | 2014-11-06 |
20140329794 | PRMT5 INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. | 2014-11-06 |
20140329795 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 2014-11-06 |
20140329796 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME - The present invention aims to provide a novel compound having a TRPA1 antagonist activity, and a medicament containing the compound. Moreover, the present invention aims to provide a TRPA1 antagonist and a medicament useful for the prophylaxis or treatment of diseases involving TRPA1. | 2014-11-06 |
20140329797 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS - The present application relates to novel substituted 5-(1,2,4-oxadiazol-5-yl)pyridin-2-ones and 6-(1,2,4-oxadiazol-5-yl)pyridazin-3-ones, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for producing medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures. | 2014-11-06 |
20140329798 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS - Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included | 2014-11-06 |
20140329799 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS - This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease. | 2014-11-06 |
20140329800 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF - The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase. | 2014-11-06 |
20140329801 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The invention relates to new sulphonylaminopyrrolidinone compounds having antithrombotic activity which, in particular, inhibit blood clotting factor IXa and/or factor Xa, to processes for their preparation and to use thereof as drugs. | 2014-11-06 |
20140329802 | TETRAHYDROBENZOTHIOPHENE COMPOUND - The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. | 2014-11-06 |
20140329803 | MUSCARINIC M1 RECEPTOR AGONISTS - This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R | 2014-11-06 |
20140329804 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF - The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5. | 2014-11-06 |
20140329805 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS - The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53. | 2014-11-06 |
20140329806 | NOVEL SOLID FORMS - The instant invention relates to novel solid forms of the compound of formula (I) | 2014-11-06 |
20140329807 | HETEROCYCLIC PROTEIN KINASE INHIBITORS - The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R | 2014-11-06 |
20140329808 | TOCOTRIENOL DERIVATIVES AND ASSOCIATED METHODS - Compositions of matter including (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine are disclosed herein. Further disclosed are methods of preparation of such compounds and the use of such compounds as anticancer agents. | 2014-11-06 |
20140329809 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF - A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea. | 2014-11-06 |
20140329810 | AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS - The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract. | 2014-11-06 |
20140329811 | Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases - The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease. | 2014-11-06 |
20140329812 | ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY - The present invention relates to aryl triazole derivatives of Formula I having antitumoural activity through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical composition containing such compounds. | 2014-11-06 |
20140329813 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 2014-11-06 |
20140329814 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases - The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions. | 2014-11-06 |
20140329815 | INHIBITORS OF C-FMS KINASE - The invention is directed to compounds of Formula I: | 2014-11-06 |
20140329816 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 2014-11-06 |
20140329817 | MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED THERETO - This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and R | 2014-11-06 |
20140329818 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 2014-11-06 |
20140329819 | INSECTICIDAL TRIAZINONE DERIVATIVES - Compounds of the formula (I) or (I′), wherein the substituents are as defined in claim | 2014-11-06 |
20140329820 | Triazine Derivatives - The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R | 2014-11-06 |
20140329821 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2014-11-06 |
20140329822 | N-PIPERIDIN-4-YL DERIVATIVES - The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders. | 2014-11-06 |
20140329823 | Dimeric IAP Inhibitors - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 2014-11-06 |
20140329824 | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN - The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof | 2014-11-06 |
20140329825 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4. | 2014-11-06 |
20140329826 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF - The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. | 2014-11-06 |
20140329828 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates - The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer. | 2014-11-06 |
20140329829 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF - The disclosure relates to Compounds of Formula (I) | 2014-11-06 |
20140329830 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE - The present invention relates to a compound of formula (I), and to pharmaceutical compositions containing said compound and to the use of said compound in therapy, for instance in treating cognitive disorders, as well as to intermediates useful in the preparation thereof. | 2014-11-06 |
20140329831 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME - The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction. | 2014-11-06 |